Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial

BACKGROUND: Advanced biliary tract cancer (ABC) has a poor prognosis. Cediranib, in addition to cisplatin/gemcitabine [CisGem], improved the response rate, but did not improve the progression-free survival (PFS) in the ABC-03 study. Minimally invasive biomarkers predictive of cediranib benefit may i...

Full description

Bibliographic Details
Main Authors:	Backen, Alison C., Lopes, Andre, Wasan, Harpreet, Palmer, Daniel H., Duggan, Marian, Cunningham, David, Anthoney, Alan, Corrie, Pippa G., Madhusudan, Srinivasan, Maraveyas, Anthony, Ross, Paul J., Waters, Justin S., Steward, William P., Rees, Charlotte, McNamara, Mairéad G., Beare, Sandy, Bridgewater, John A., Dive, Caroline, Valle, Juan W.
Format:	Article
Language:	English
Published:	2018
Online Access:	http://eprints.nottingham.ac.uk/52543/ http://eprints.nottingham.ac.uk/52543/ http://eprints.nottingham.ac.uk/52543/ http://eprints.nottingham.ac.uk/52543/1/s41416-018-0132-8.pdf

Internet

http://eprints.nottingham.ac.uk/52543/
http://eprints.nottingham.ac.uk/52543/
http://eprints.nottingham.ac.uk/52543/
http://eprints.nottingham.ac.uk/52543/1/s41416-018-0132-8.pdf

Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial

Internet

Similar Items